Maze Therapeutics MAZE Institutional Ownership

Updated Oct 11, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE) was held by 162 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Together they owned 99.22% of the outstanding stock in Q2 2026, up from 95.88% a quarter earlier.
• Total holdings of Maze Therapeutics shares rose 13.27% from Q1 2026, and the number of holders rose 121.92% from Q2 2025.
• Looking at the 162 holders of MAZE individually, 105 added to their positions, 38 reduced their stakes and 19 left their positions unchanged.
• In total, institutional investors held 58.53Mn shares of Maze Therapeutics at the end of Q2 2026, up 6.86Mn from the prior quarter and up 19.73Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Maze Therapeutics was Frazier Life Sciences Management, L.P. with 5.03Mn shares, or 8.53% of shares outstanding.
• Among holders that already owned Maze Therapeutics, the biggest buyers in Q2 2026 were BlackRock, Inc. (+932.42K shares), JPMorgan Chase & Co (+905.57K shares), Farallon Capital Management, L.L.C. (+734.81K shares), Logos Global Management LP (+700K shares) and Marshall Wace, LLP (+603.93K shares).
• The biggest cuts to MAZE positions during Q2 2026 came from Adage Capital Partners GP, L.L.C. (-930K shares), Balyasny Asset Management L.P. (-440.96K shares), Boothbay Fund Management, LLC (-95.62K shares), Ensign Peak Advisors, Inc (-84.15K shares) and Morgan Stanley (-69.66K shares).
• Maze Therapeutics' 10 largest institutional shareholders as of Q2 2026 were Frazier Life Sciences Management, L.P. (5.03Mn shares), TRV GP IV, LLC (4.47Mn shares), ARCH Venture Management, LLC (4.12Mn shares), Deep Track Capital, LP (3.73Mn shares), BlackRock, Inc. (3.5Mn shares), Jupiter Topco LLC (3.41Mn shares), T. Rowe Price Investment Management, Inc. (2.6Mn shares), Logos Global Management LP (1.94Mn shares), Vanguard Capital Management LLC (1.78Mn shares) and a16z Capital Management, L.L.C. (1.7Mn shares), per Business Quant data.